Johimbin

Johimbin
(IUPAC) ime
	17α-hidroksi-johimban-16α-; metil estar karboksilne kiseline
Klinički podaci
Robne marke	Yocon
Identifikatori
CAS broj	146-48-5
ATC kod	G04BE04 QV03AB93
PubChem	8969
DrugBank	DB01392
ChemSpider	8622
UNII	2Y49VWD90Q
ChEBI	CHEBI:10093
ChEMBL	CHEMBL15245
Hemijski podaci
Formula	C21H26N2O3
Mol. masa	354,44 g/mol (baza); 390,90 g/mol (hidrohlorid)
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15-,17-,18-,19+/m0/s1 ; Key: BLGXFZZNTVWLAY-SCYLSFHTSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	OTC
Način primene	Oralno

Johimbin je alkaloid sa stimulantnim i afrodizijskim dejstvom koji se prirodno javlja u biljci Pausinystalia yohimbe. On se takođe prirodno javlja u Rauwolfia serpentina i Alchornea floribunda, zajedno sa nekoliko drugih alkaloida. Johimbin je korišten kao dijetarni suplement u obliku biljnog ekstrakta i kao lek na recepat u čistoj formi za tretman seksualne disfunkcije. Johimbin je izučavan kao lek za tip 2 dijabetes.^[5]

Farmakologija uredi

Johimbin ima visok afinitet za α₂-adrenergički receptor, umereni afinitet za α₁-adrenergički, 5-HT_1A, 5-HT_1B, 5-HT_1D, 5-HT_1F, 5-HT_2B, i D₂ receptore, i slab afinitet za 5-HT_1E, 5-HT_2A, 5-HT_5A, 5-HT₇, i D₃ receptore.^[6]^[7] On deluje kao antagonist na α₁-adrenergičkom, α₂-adrenergičkom, 5-HT_1B, 5-HT_1D, 5-HT_2A, 5-HT_2B, i D₂, i kao parcijalni agonist na 5-HT_1A.^[6]^[8]^[9]^[10]

Reference uredi

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Rosengren, A. H.; Jokubka, R.; Tojjar, D.; Granhall, C.; Hansson, O.; Li, D.-Q.; Nagaraj, V.; Reinbothe, T. M. i dr.. (2009). „Overexpression of Alpha2A-Adrenergic Receptors Contributes to Type 2 Diabetes”. Science 327 (5962): 217–20. DOI:10.1126/science.1176827. PMID 19965390.
↑ ^6,0 ^6,1 Millan MJ, Newman-Tancredi A, Audinot V i dr.. (February 2000). „Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states”. Synapse 35 (2): 79–95. DOI:10.1002/(SICI)1098-2396(200002)35:2<79::AID-SYN1>3.0.CO;2-X. PMID 10611634.
↑ „PDSP Ki Database”. Arhivirano iz originala na datum 2013-11-08. Pristupljeno 2014-04-05.
↑ Arthur JM, Casañas SJ, Raymond JR (June 1993). „Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors”. Biochemical Pharmacology 45 (11): 2337–41. DOI:10.1016/0006-2952(93)90208-E. PMID 8517875.
↑ Kaumann AJ (June 1983). „Yohimbine and rauwolscine inhibit 5-hydroxytryptamine-induced contraction of large coronary arteries of calf through blockade of 5 HT2 receptors”. Naunyn-Schmiedeberg's Archives of Pharmacology 323 (2): 149–54. DOI:10.1007/BF00634263. PMID 6136920.
↑ Baxter GS, Murphy OE, Blackburn TP (May 1994). „Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle”. British Journal of Pharmacology 112 (1): 323–31. PMC 1910288. PMID 8032658.

Spoljašnje veze uredi

	Portal Medicina
	Portal Hemija

Yohimbe bark extract

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[5] Rosengren, A. H.; Jokubka, R.; Tojjar, D.; Granhall, C.; Hansson, O.; Li, D.-Q.; Nagaraj, V.; Reinbothe, T. M. i dr.. (2009). „Overexpression of Alpha2A-Adrenergic Receptors Contributes to Type 2 Diabetes”. Science 327 (5962): 217–20. DOI:10.1126/science.1176827. PMID 19965390.

[pmid10611634-6] 6,0 ^6,1 Millan MJ, Newman-Tancredi A, Audinot V i dr.. (February 2000). „Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states”. Synapse 35 (2): 79–95. DOI:10.1002/(SICI)1098-2396(200002)35:2<79::AID-SYN1>3.0.CO;2-X. PMID 10611634.

[urlPDSP_Ki_Database-7] „PDSP Ki Database”. Arhivirano iz originala na datum 2013-11-08. Pristupljeno 2014-04-05.

[pmid8517875-8] Arthur JM, Casañas SJ, Raymond JR (June 1993). „Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors”. Biochemical Pharmacology 45 (11): 2337–41. DOI:10.1016/0006-2952(93)90208-E. PMID 8517875.

[pmid6136920-9] Kaumann AJ (June 1983). „Yohimbine and rauwolscine inhibit 5-hydroxytryptamine-induced contraction of large coronary arteries of calf through blockade of 5 HT2 receptors”. Naunyn-Schmiedeberg's Archives of Pharmacology 323 (2): 149–54. DOI:10.1007/BF00634263. PMID 6136920.

[pmid8032658-10] Baxter GS, Murphy OE, Blackburn TP (May 1994). „Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle”. British Journal of Pharmacology 112 (1): 323–31. PMC 1910288. PMID 8032658.

[5]

[1]

[2]

[3]

[4]

[6]

[7]

[8]

[9]

[10]